(Korean Source)

Translated title of the contribution: Correlation Of early systemic recurrence with in vitro adenosine triphosphatebased chemotherapy response assay in stage II and III breast cancer patients treated with doxorubicin-based chemotherapy

Sung Gwe Ahn, Joon Jeong, Suk Kyung Choi, Seung Hyun Hwang, Seunge Ah Lee, Woo Hee Jung, Hy De Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: An in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was designed to require only a limited number of cells and shorten test turnaround time with a high success rate. This study investigated the correlation between in vitro doxorubicin sensitivity of tumor cells and early systemic recurrence, defined as recurrence with in 2 years after surgery. Methods: From January 2004 to March 2007, the ATP-CRA for doxorubicin was tested in 128 patients among breast cancer patients treated at Gangnam Severance Hospital, Seoul, Korea. The American Joint Committee on Cancer stages for all patients were II and III. All patients received doxorubicin-based chemotherapy. Selected patients were divided into a chemosensitive group and a non-chemosensitive group, according to a 40% cell death rate as a cut-off value. We analyzed the relationship between chemosensitivity and early systemic recurren e in patients with breast cancer. Results: The mean age of the patients investigated was 44.6-years old, the mean follow-up period was 39.9 months, and recurrence free survival was 38.6 months. Thirteen recurrences were observed during follow-up. Among 13 patients with a recurrence, eight had a recurrence within 2 years (early recurrence). All of the early recurring patients belonged to the non-sensitive group. Doxorubicin sensitivity results measured by ATP-CRA were related with early recurrence free survival in patients with breast cancer (p=0.030). The mean cell death rate derived from the ATP-CRA for the early recurrence group tended to be lower than that of the non-early recurrence group, but the difference was not statistically significant (p=0.05). Conclusion: Doxorubicin sensitivity measured by ATP-CRA was well correlated with in vivo drug responsibility to predict early recurrence against doxorubicinbased adjuvant chemotherapy in patients with breast cancer.

Original languageKorean
Pages (from-to)S50-S56
JournalJournal of Breast Cancer
Volume14
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2011 Feb 1

Fingerprint

Adenosine
Doxorubicin
Breast Neoplasms
Recurrence
Drug Therapy
Adenosine Triphosphate
In Vitro Techniques
Cell Death
Survival
Mortality
Adjuvant Chemotherapy
Korea
Neoplasms
Cell Count

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ahn, S. G., Jeong, J., Choi, S. K., Hwang, S. H., Lee, S. A., Jung, W. H., & Lee, H. D. (2011). (Korean Source). Journal of Breast Cancer, 14(SUPPL. 1), S50-S56. https://doi.org/10.4048/jbc.2011.14.S.S50
Ahn, Sung Gwe ; Jeong, Joon ; Choi, Suk Kyung ; Hwang, Seung Hyun ; Lee, Seunge Ah ; Jung, Woo Hee ; Lee, Hy De. / (Korean Source). In: Journal of Breast Cancer. 2011 ; Vol. 14, No. SUPPL. 1. pp. S50-S56.
@article{7e93005324cb4bdba78f37c11db547ef,
title = "(Korean Source)",
abstract = "Purpose: An in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was designed to require only a limited number of cells and shorten test turnaround time with a high success rate. This study investigated the correlation between in vitro doxorubicin sensitivity of tumor cells and early systemic recurrence, defined as recurrence with in 2 years after surgery. Methods: From January 2004 to March 2007, the ATP-CRA for doxorubicin was tested in 128 patients among breast cancer patients treated at Gangnam Severance Hospital, Seoul, Korea. The American Joint Committee on Cancer stages for all patients were II and III. All patients received doxorubicin-based chemotherapy. Selected patients were divided into a chemosensitive group and a non-chemosensitive group, according to a 40{\%} cell death rate as a cut-off value. We analyzed the relationship between chemosensitivity and early systemic recurren e in patients with breast cancer. Results: The mean age of the patients investigated was 44.6-years old, the mean follow-up period was 39.9 months, and recurrence free survival was 38.6 months. Thirteen recurrences were observed during follow-up. Among 13 patients with a recurrence, eight had a recurrence within 2 years (early recurrence). All of the early recurring patients belonged to the non-sensitive group. Doxorubicin sensitivity results measured by ATP-CRA were related with early recurrence free survival in patients with breast cancer (p=0.030). The mean cell death rate derived from the ATP-CRA for the early recurrence group tended to be lower than that of the non-early recurrence group, but the difference was not statistically significant (p=0.05). Conclusion: Doxorubicin sensitivity measured by ATP-CRA was well correlated with in vivo drug responsibility to predict early recurrence against doxorubicinbased adjuvant chemotherapy in patients with breast cancer.",
author = "Ahn, {Sung Gwe} and Joon Jeong and Choi, {Suk Kyung} and Hwang, {Seung Hyun} and Lee, {Seunge Ah} and Jung, {Woo Hee} and Lee, {Hy De}",
year = "2011",
month = "2",
day = "1",
doi = "10.4048/jbc.2011.14.S.S50",
language = "Korean",
volume = "14",
pages = "S50--S56",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "SUPPL. 1",

}

Ahn, SG, Jeong, J, Choi, SK, Hwang, SH, Lee, SA, Jung, WH & Lee, HD 2011, '(Korean Source)', Journal of Breast Cancer, vol. 14, no. SUPPL. 1, pp. S50-S56. https://doi.org/10.4048/jbc.2011.14.S.S50

(Korean Source). / Ahn, Sung Gwe; Jeong, Joon; Choi, Suk Kyung; Hwang, Seung Hyun; Lee, Seunge Ah; Jung, Woo Hee; Lee, Hy De.

In: Journal of Breast Cancer, Vol. 14, No. SUPPL. 1, 01.02.2011, p. S50-S56.

Research output: Contribution to journalArticle

TY - JOUR

T1 - (Korean Source)

AU - Ahn, Sung Gwe

AU - Jeong, Joon

AU - Choi, Suk Kyung

AU - Hwang, Seung Hyun

AU - Lee, Seunge Ah

AU - Jung, Woo Hee

AU - Lee, Hy De

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Purpose: An in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was designed to require only a limited number of cells and shorten test turnaround time with a high success rate. This study investigated the correlation between in vitro doxorubicin sensitivity of tumor cells and early systemic recurrence, defined as recurrence with in 2 years after surgery. Methods: From January 2004 to March 2007, the ATP-CRA for doxorubicin was tested in 128 patients among breast cancer patients treated at Gangnam Severance Hospital, Seoul, Korea. The American Joint Committee on Cancer stages for all patients were II and III. All patients received doxorubicin-based chemotherapy. Selected patients were divided into a chemosensitive group and a non-chemosensitive group, according to a 40% cell death rate as a cut-off value. We analyzed the relationship between chemosensitivity and early systemic recurren e in patients with breast cancer. Results: The mean age of the patients investigated was 44.6-years old, the mean follow-up period was 39.9 months, and recurrence free survival was 38.6 months. Thirteen recurrences were observed during follow-up. Among 13 patients with a recurrence, eight had a recurrence within 2 years (early recurrence). All of the early recurring patients belonged to the non-sensitive group. Doxorubicin sensitivity results measured by ATP-CRA were related with early recurrence free survival in patients with breast cancer (p=0.030). The mean cell death rate derived from the ATP-CRA for the early recurrence group tended to be lower than that of the non-early recurrence group, but the difference was not statistically significant (p=0.05). Conclusion: Doxorubicin sensitivity measured by ATP-CRA was well correlated with in vivo drug responsibility to predict early recurrence against doxorubicinbased adjuvant chemotherapy in patients with breast cancer.

AB - Purpose: An in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was designed to require only a limited number of cells and shorten test turnaround time with a high success rate. This study investigated the correlation between in vitro doxorubicin sensitivity of tumor cells and early systemic recurrence, defined as recurrence with in 2 years after surgery. Methods: From January 2004 to March 2007, the ATP-CRA for doxorubicin was tested in 128 patients among breast cancer patients treated at Gangnam Severance Hospital, Seoul, Korea. The American Joint Committee on Cancer stages for all patients were II and III. All patients received doxorubicin-based chemotherapy. Selected patients were divided into a chemosensitive group and a non-chemosensitive group, according to a 40% cell death rate as a cut-off value. We analyzed the relationship between chemosensitivity and early systemic recurren e in patients with breast cancer. Results: The mean age of the patients investigated was 44.6-years old, the mean follow-up period was 39.9 months, and recurrence free survival was 38.6 months. Thirteen recurrences were observed during follow-up. Among 13 patients with a recurrence, eight had a recurrence within 2 years (early recurrence). All of the early recurring patients belonged to the non-sensitive group. Doxorubicin sensitivity results measured by ATP-CRA were related with early recurrence free survival in patients with breast cancer (p=0.030). The mean cell death rate derived from the ATP-CRA for the early recurrence group tended to be lower than that of the non-early recurrence group, but the difference was not statistically significant (p=0.05). Conclusion: Doxorubicin sensitivity measured by ATP-CRA was well correlated with in vivo drug responsibility to predict early recurrence against doxorubicinbased adjuvant chemotherapy in patients with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=79952966068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952966068&partnerID=8YFLogxK

U2 - 10.4048/jbc.2011.14.S.S50

DO - 10.4048/jbc.2011.14.S.S50

M3 - Article

AN - SCOPUS:79952966068

VL - 14

SP - S50-S56

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - SUPPL. 1

ER -

Ahn SG, Jeong J, Choi SK, Hwang SH, Lee SA, Jung WH et al. (Korean Source). Journal of Breast Cancer. 2011 Feb 1;14(SUPPL. 1):S50-S56. https://doi.org/10.4048/jbc.2011.14.S.S50